Latest & greatest articles for adalimumab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adalimumab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adalimumab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adalimumab

61. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of t (PubMed)

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of t To assess the safety and efficacy of ixekizumab, a monoclonal antibody that inhibits interleukin-17A, in a double-blind phase III trial enrolling patients with active psoriatic arthritis (PsA).Patients naive to biologic therapy with active PsA (...) were randomised to subcutaneous injections of placebo (N=106), adalimumab 40 mg once every 2 weeks (active reference; N=101), ixekizumab 80 mg once every 2 weeks (IXEQ2W) (N=103), or ixekizumab 80 mg once every 4 weeks (IXEQ4W) (N=107). Both ixekizumab regimens included a 160-mg starting dose. The primary objective was to assess the superiority of IXEQ2W or IXEQ4W versus placebo as measured by the proportion of patients achieving an American College of Rheumatology 20 (ACR20) response at week 24

Full Text available with Trip Pro

2016 EvidenceUpdates

62. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. (PubMed)

Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Non-infectious uveitis is a potentially sight-threatening ocular disorder caused by chronic inflammation and its complications. Therapeutic success is limited by systemic adverse effects associated with long-term corticosteroid and immunomodulator use if topical medication (...) is not sufficient to control the inflammation. We aimed to assess the efficacy and safety of adalimumab in patients with inactive, non-infectious uveitis controlled by systemic corticosteroids.We did this multicentre, double-masked, randomised, placebo-controlled phase 3 trial at 62 study sites in 21 countries in the USA, Canada, Europe, Israel, Australia, and Latin America. Patients (aged ≥18 years) with inactive, non-infectious intermediate, posterior, or panuveitic uveitis controlled by 10-35 mg/day

Full Text available with Trip Pro

2016 Lancet

63. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. (PubMed)

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. Hidradenitis suppurativa is a painful, chronic inflammatory skin disease with few options for effective treatment. In a phase 2 trial, adalimumab, an antibody against tumor necrosis factor α, showed efficacy against hidradenitis suppurativa.PIONEER I and II were similarly designed, phase 3 multicenter trials of adalimumab for hidradenitis suppurativa, with two double-blind, placebo-controlled periods. In period 1, patients were (...) randomly assigned in a 1:1 ratio to 40 mg of adalimumab weekly or matching placebo for 12 weeks. In period 2, patients were reassigned to adalimumab at a weekly or every-other-week dose or to placebo for 24 weeks. The primary end point was a clinical response, defined as at least a 50% reduction from baseline in the abscess and inflammatory-nodule count, with no increase in abscess or draining-fistula counts, at week 12.We enrolled 307 patients in PIONEER I and 326 in PIONEER II. Clinical response

2016 NEJM

64. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis (PubMed)

Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis Adalimumab has been used in patients with moderately to severely active rheumatoid arthritis (RA) for over 10 years and has a well-established safety profile across multiple indications.To update adverse events (AEs) of special interest from global adalimumab clinical trials in patients with RA.This analysis includes 15 132 patients exposed to adalimumab in global RA (...) clinical trials. AEs of interest included overall infections, laboratory abnormalities and AEs associated with influenza vaccination. Pregnancy outcome data were collected from the Adalimumab Pregnancy Registry.Serious infections and tuberculosis occurred at a rate of 4.7 and 0.3 events/100 patient-years, respectively. Two patients experienced hepatitis B reactivation. No significant laboratory abnormalities were reported with adalimumab-plus-methotrexate compared with placebo-plus-methotrexate

Full Text available with Trip Pro

2016 EvidenceUpdates

65. Adalimumab (Humira) for uveitis in paediatric patients - second line

Adalimumab (Humira) for uveitis in paediatric patients - second line Adalimumab (Humira) for uveitis in paediatric patients – second line Adalimumab (Humira) for uveitis in paediatric patients – second line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Adalimumab (Humira) for uveitis in paediatric patients – second line. Birmingham: NIHR (...) Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Uveitis affects the lining of the eye. It is an inflammation that can lead to eye pain, eye redness, headaches, and visual problems that can become permanent. In many cases the cause of uveitis is unknown, but it is much more common in patients who are affected by a form of childhood arthritis called juvenile idiopathic arthritis (JIA). Adalimumab is a drug that is already used to treat JIA

2016 Health Technology Assessment (HTA) Database.

66. Adalimumab (Humira) and plaque psoriasis in children: no better than other immunosuppressants

Adalimumab (Humira) and plaque psoriasis in children: no better than other immunosuppressants Prescrire IN ENGLISH - Spotlight ''In the July issue of Prescrire International - Adalimumab (Humira°) and plaque psoriasis in children: no better than other immunosuppressants'', 1 July 2016 {1} {1} {1} | | > > > In the July issue of Prescrire International - Adalimumab (Humira°) and plaque psoriasis in children: no better than other immunosuppressants Spotlight Every month, the subjects (...) in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight In the July issue of Prescrire International - Adalimumab (Humira°) and plaque psoriasis in children: no better than other immunosuppressants FREE DOWNLOAD In a trial in 114 children, the efficacy of adalimumab was not notably different from that of methotrexate, and its adverse effects profile did not appear to be more favourable. Full text

2016 Prescrire

67. Adalimumab for treating moderate to severe hidradenitis suppurativa

Adalimumab for treating moderate to severe hidradenitis suppurativa Adalimumab for treating moder Adalimumab for treating moderate to ate to se sev vere hidr ere hidradenitis suppur adenitis suppurativa ativa T echnology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta392 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance (...) inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 43Contents Contents 1 Recommendations 4 2 The technology 5

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

68. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model

Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262):clinical effectiveness systematic review and economic model Journals Library

2016 NIHR HTA programme

69. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifyin

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifyin Adalimumab, etanercept, infliximab,certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional

2016 NIHR HTA programme

70. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation

The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page

2016 NIHR HTA programme

71. Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis

Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis Abatacept, adalimumab, etanercept and Abatacept, adalimumab, etanercept and tocilizumab for treating juv tocilizumab for treating juvenile enile idiopathic arthritis idiopathic arthritis T echnology appraisal guidance Published: 16 December 2015 nice.org.uk/guidance/ta373 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y (...) to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373) © NICE 2019. All rights reserved. Subject to Notice of rights (https

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

72. Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study) (PubMed)

Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study) There is insufficient evidence regarding the appropriate dose of methotrexate (MTX) required to achieve specific treatment goals in patients with rheumatoid arthritis (RA) receiving biologic drugs in Japan. The present study aimed to assess the dose-response effect of MTX in combination with adalimumab (ADA) to achieve low disease activity

Full Text available with Trip Pro

2015 Rheumatology and therapy

73. A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis (PubMed)

A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis Enthesitis-related arthritis (ERA) is a juvenile idiopathic arthritis (JIA) category, primarily affecting entheses and peripheral joints. This study evaluated efficacy, safety, and pharmacokinetics of adalimumab versus placebo in patients with ERA.This is a phase III, multicenter, randomized double-blind study in patients ages ≥6 to <18 years with ERA treated (...) with adalimumab (24 mg/m(2) , maximum dose 40 mg every other week) or placebo for 12 weeks, followed by up to 192 weeks of open-label adalimumab. The primary end point was percent change from baseline in number of active joints with arthritis (AJC) at week 12. Samples were collected to determine adalimumab serum concentrations. Adverse events (AEs) were assessed throughout the study.Forty-six patients were randomized (31 adalimumab/15 placebo). At baseline, mean age was 12.9 years, mean duration of ERA

Full Text available with Trip Pro

2015 EvidenceUpdates

74. Adalimumab (Humira)

Adalimumab (Humira) Adalimumab | CADTH.ca Find the information you need Adalimumab Adalimumab Last Updated: September 13, 2018 Result type: Reports Project Number: SR0455-000 Product Line: Generic Name: Adalimumab Brand Name: Humira Manufacturer: AbbVie Corporation Indications: Hidradenitis suppurativa Submission Type: New Indication Project Status: Complete Date Recommendation Issued: May 19, 2016 Recommendation Type: Reimburse with clinical criteria and/or conditions Tags hidradenitis

2015 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

75. Adalimumab (Humira®)

Adalimumab (Humira®) Adalimumab (Humira®) Adalimumab (Humira®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Adalimumab (Humira®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat (...) Assessment Report Advice No. 2562. 2015 Authors' conclusions Adalimumab (Humira®) is recommended as an option for use within NHS Wales for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Humans Language Published

2015 Health Technology Assessment (HTA) Database.

76. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. (PubMed)

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. Little is known about the effect of specific anti-interleukin-23 therapy, as compared with established anti-tumor necrosis factor therapies, for the treatment of moderate-to-severe plaque psoriasis.In a 52-week, phase 2, dose-ranging, randomized, double-blind, placebo-controlled, active-comparator trial, we compared guselkumab (CNTO 1959), an anti-interleukin-23 monoclonal antibody, with adalimumab in patients with moderate (...) -to-severe plaque psoriasis. A total of 293 patients were randomly assigned to receive guselkumab (5 mg at weeks 0 and 4 and every 12 weeks thereafter, 15 mg every 8 weeks, 50 mg at weeks 0 and 4 and every 12 weeks thereafter, 100 mg every 8 weeks, or 200 mg at weeks 0 and 4 and every 12 weeks thereafter) through week 40, placebo, or adalimumab (standard dosage for psoriasis). At week 16, patients in the placebo group crossed over to receive guselkumab at a dose of 100 mg every 8 weeks. The primary end

2015 NEJM

77. Adalimumab (Humira) - for the treatment of active enthesitis-related arthritis

Adalimumab (Humira) - for the treatment of active enthesitis-related arthritis AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA373) NICE GUIDANCE ISSUED DECEMBER 2015 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Final Appraisal Recommendation Advice No: 1015 – April 2015 Adalimumab (Humira ® ) 40 mg solution for injection in pre-filled syringe and pre-filled pen, 40 mg/0.8 ml solution for injection single use (...) (where available), the views of patients/patient carers (where available) and the lay member perspective. This recommendation has been ratified by the Minister for Health and Social Services and will be considered for review every three years. Recommendation of AWMSG Adalimumab (Humira ® ) is recommended as an option for use within NHS Wales for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant

2015 All Wales Medicines Strategy Group

78. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA) (PubMed)

Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA) Published evidence on the long-term safety of etanercept (ETA) and adalimumab (ADA) in patients with polyarticular juvenile idiopathic arthritis (pJIA) is still limited.To investigate the rates of serious adverse events (SAE) and of events of special interest (ESI) under ETA and ADA treatment.Patients with pJIA were prospectively observed in the national JIA biological

2015 EvidenceUpdates

79. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. (PubMed)

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. To evaluate whether a disease activity guided strategy of dose reduction of two tumour necrosis factor (TNF) inhibitors, adalimumab or etanercept, is non-inferior in maintaining disease control in patients with rheumatoid arthritis compared with usual care.Randomised controlled, open label, non-inferiority (...) strategy trial.Two rheumatology outpatient clinics in the Netherlands, from December 2011 to May 2014.180 patients with rheumatoid arthritis and low disease activity using adalimumab or etanercept; 121 allocated to the dose reduction strategy, 59 to usual care.Disease activity guided dose reduction (advice to stepwise increase the injection interval every three months, until flare of disease activity or discontinuation) or usual care (no dose reduction advice). Flare was defined as increase in DAS28

Full Text available with Trip Pro

2015 BMJ

80. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. (PubMed)

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. To evaluate whether a disease activity guided strategy of dose reduction of two tumour necrosis factor (TNF) inhibitors, adalimumab or etanercept, is non-inferior in maintaining disease control in patients with rheumatoid arthritis compared with usual care.Randomised controlled, open label, non-inferiority (...) strategy trial.Two rheumatology outpatient clinics in the Netherlands, from December 2011 to May 2014.180 patients with rheumatoid arthritis and low disease activity using adalimumab or etanercept; 121 allocated to the dose reduction strategy, 59 to usual care.Disease activity guided dose reduction (advice to stepwise increase the injection interval every three months, until flare of disease activity or discontinuation) or usual care (no dose reduction advice). Flare was defined as increase in DAS28

Full Text available with Trip Pro

2015 BMJ